Project Grant R01CA299863
Award Date 8/18/25
Completion Date 7/31/30
Dollars Obligated $604K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Madison, WI 53715, USA
Similar Awards
- This $680,433 Project Grant awarded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) will fund research to improve prognostic estimation and understand the underlying biology of prostate cancer. The University of California, San Francisco (UCSF) will employ advanced spatial proteogenomic analysis technologies, alongside pathology artificial intelligence (PAI) algorithms, to identify novel genomic and proteomic markers that can explain and enhance...
- This Project Grant award, totaling $1,360,906, was provided by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to investigate the use of cell-free DNA fragmentomics as prognostic and treatment resistance biomarkers in metastatic castration-resistant prostate cancer (MCRPC). The award will fund a study with three specific aims: 1) determine if baseline circulating tumor DNA (ctDNA) fragmentomics scores are prognostic biomarkers in MCRPC, 2) detect the...
- This federal Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $681,215.00 to New York University (NYU) School of Medicine to develop novel machine learning models that can accurately infer the presence of prostate cancer from minimal, degraded magnetic resonance imaging (MRI) data. The goal is to enable point-of-care MRI devices for widespread population-level screening and early detection of clinically significant...
- The University of Delaware was awarded a $245,087 federal Project Grant from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) to integrate radiologist insights for safe and accurate AI-assisted prostate MRI interpretation. The grant, awarded on June 1, 2025, with a completion date of May 31, 2027, will fund research to develop a Prostate Vision Language Model (ProVLM) that can learn from both visual data (e.g., lesion annotations) and text data...
- The National Cancer Institute (NCI) awarded a Project Grant of $677,998 to the Medical College of Wisconsin (MCW) under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The grant, effective from February 1, 2025 to January 31, 2030, aims to externally validate and integrate radio-pathomic models developed using autopsy and biopsy samples from MCW and the University of California, San Francisco. The models will be further refined and validated through the inclusion of clinical...
- This federal Project Grant award of $568,151 from the National Cancer Institute (CFDA 93.394 Cancer Detection and Diagnosis Research) is supporting the development of a real-time photoacoustic imaging platform to accurately detect and characterize prostate cancer aggressiveness. The project, led by the Regents of the University of Michigan, aims to leverage advanced photoacoustic imaging and biocompatible hydrogel nanoparticle probes to quantitatively assess prostate gland microarchitecture...
- This National Cancer Institute (CFDA 93.394 Cancer Detection and Diagnosis Research) Project Grant award of $683,089 to the Sloan-Kettering Institute for Cancer Research supports the development of an improved, interpretable deep learning algorithm called DeepLIIF for more reproducible and accurate PD-L1 immunohistochemistry (IHC) biomarker quantification. The goal is to leverage virtual multiplex immunofluorescence (MPIF) restaining and large, diverse datasets across lung and bladder cancers to...
- The University of Wisconsin System was awarded a $2,579,971 Project Grant from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) on August 11, 2025. The grant, which runs through July 31, 2030, supports research aimed at understanding the molecular drivers and therapeutic susceptibilities of lineage state transitions in metastatic prostate cancer. Key objectives include studying the regulation of androgen receptor transcriptional states in distinct...
- This $538,553 Project Grant was awarded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to the University of Miami to define the role of quantitative multiparametric MRI and circulating tumor cells as early markers of patient outcome after radiotherapy and androgen deprivation therapy in intermediate and high-risk prostate cancer patients. The primary early endpoint is freedom from biochemical nadir thresholds at 9 months. The project will be conducted...
- This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $399,954 to Metastx LLC, a small business located in Pennsylvania, to develop a novel predictive model for metastatic potential in early-stage prostate cancer patients. The project aims to enhance prostate cancer prognostication by integrating epithelial-to-mesenchymal transition (EMT) signature markers with advanced imaging and machine learning techniques. By...